The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Size Is Forecasted For The Interstitial Lung Disease Market By 2030 Based On Its 2026 Value?

The interstitial lung disease market has experienced robust growth in recent years. It is projected to expand from $2.09 billion in 2025 to $2.24 billion in 2026, at a compound annual growth rate (CAGR) of 7.2%. Historically, the expansion of this market can be attributed to the rising prevalence of chronic respiratory diseases, increased exposure to occupational and environmental pollutants, advancements in pulmonary imaging techniques, improved awareness of idiopathic pulmonary fibrosis, and the expansion of specialty pulmonary clinics.

The interstitial lung disease market is projected to experience substantial expansion over the upcoming years, with its size anticipated to reach $3.09 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.4%. This expected growth during the forecast period is primarily attributed to an expanding aging population, increasing diagnosis rates of interstitial lung disorders, a greater adoption of targeted anti-fibrotic drugs, the expansion of research into novel ILD therapies, and improved patient screening and monitoring programs. Furthermore, significant trends in this period include a heightened emphasis on early and accurate ILD diagnosis, the growing acceptance of anti-fibrotic therapies, an increased focus on managing disease progression, the broadening of multidisciplinary care approaches, and enhanced access to long-term ILD treatment.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13019&type=smp

Which Significant Factors Are Encouraging Growth In The Interstitial Lung Disease Market?

The interstitial lung disease market is projected to grow due to the increasing prevalence of autoimmune ailments. Autoimmune ailments are health conditions where the immune system mistakenly attacks the body’s healthy cells and tissues. This rise in autoimmune ailments impacts the interstitial lung disease market by heightening the demand for ILD-related healthcare services, encouraging research and development, and advancing therapies and patient care. For example, in September 2023, the Institute for Health Metrics and Evaluation, a US-based global health research center, estimated that global rheumatoid arthritis cases are expected to reach 31.7 million by 2050, showing a notable increase over this period. Hence, the increasing occurrence of autoimmune ailments is propelling the expansion of the interstitial lung disease market.

Which Segment-Based Categories Are Covered In The Interstitial Lung Disease Market?

The interstitial lung disease market covered in this report is segmented –

1) By Drug Type: Oral Corticosteroids, Immune Suppressing, Anti-Fibrotic Medication, Other Drugs

2) By Disease Type: Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonitis, Hypersensitivity Pneumonitis, Cryptogenic Organizing Pneumonia (COP), Sarcoidosis, Acute Interstitial Pneumonitis

3) By Application: Adults, Children

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Oral Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone

2) By Immune Suppressing: Azathioprine, Methotrexate, Mycophenolate Mofetil

3) By Anti-Fibrotic Medication: Pirfenidone, Nintedanib

4) By Other Drugs: Antioxidants, Anticoagulants, Other Novel Therapies

Which Trends Are Contributing To Changes In The Interstitial Lung Disease Market?

Key companies active in the interstitial lung disease market are prioritizing product launches, particularly innovative therapies for conditions like idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. Idiopathic pulmonary fibrosis (IPF) stands as a chronic, progressive lung ailment marked by tissue scarring, which subsequently impairs breathing and diminishes oxygen transfer. As an example, in February 2024, C.H. Boehringer Sohn AG & Co. KG, a biopharmaceutical firm headquartered in Germany, obtained FDA approval for its BI 1015550 Therapy, intended for the management of Idiopathic Pulmonary Fibrosis. BI 1015550 represents an investigational oral treatment designed to inhibit phosphodiesterase 4B (PDE4B), exhibiting antifibrotic and anti-inflammatory properties geared towards decelerating the decline in lung function for individuals with idiopathic pulmonary fibrosis (IPF).

Who Are The Key Market Participants In The Interstitial Lung Disease Market?

Major companies operating in the interstitial lung disease market are Roche Laboratories Inc., Merck & Co. Inc., Bayer AG, Novartis Pharmaceuticals Corporation, The Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceuticals USA Inc., AstraZeneca plc, Horizon Pharma USA Inc., Genentech Inc., Amneal Pharmaceuticals LLC, Insmed Inc., EmphyCorp Inc., Verseau Therapeutics, Regend Therapeutics Co., LTT Bio-Pharma Co. Ltd., Galecto Biotech, Pulmatrix Inc., PureTech Health plc, Pneuma Respiratory Inc., Bellerophon Therapeutics Inc., MediciNova Inc., Altavant Sciences Inc., Verona Pharma plc

Access The Complete Interstitial Lung Disease Market Report:

https://www.thebusinessresearchcompany.com/report/interstitial-lung-disease-global-market-report

Which Region Stands As The Largest Contributor To The Interstitial Lung Disease Market?

North America was the largest region in the interstitial lung disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interstitial lung disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Interstitial Lung Disease Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=13019&type=smp

Browse Through More Reports Similar to the Global Interstitial Lung Disease Market 2026, By The Business Research Company

Peripheral Arterial Disease Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-arterial-disease-global-market-report

Muscle Spasticity Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/muscle-spasticity-global-market-report

Hearing Loop Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/hearing-loop-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.